Author:
Lawasut Panisinee,Chauhan Dharminder,Laubach Jacob,Hayes Catriona,Fabre Claire,Maglio Michelle,Mitsiades Constantine,Hideshima Teru,Anderson Kenneth C.,Richardson Paul G.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference60 articles.
1. Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009;23(12):2222–32.
2. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005;4(2):290–6.
3. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(4):667–75.
4. Kirk CJ. Discovery and development of second-generation proteasome inhibitors. Semin Hematol. 2012;49(3):207–14.
5. •• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: ten years later. Blood. 2012 May 29. A comprehensive review of PIs, both old and new.
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献